Conversely, in the tirzepatide 10 and 15 mg treatment groups, a numerically greater reduction in SMBG profiles was observed in patients with a higher baseline HbA1c, but the difference did not reach statistical significance (Supplementary Fig. 2).
← all excerpts
Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups.
1
—
—